ReviewBritish journal of cancer2021
Tumour treating fields therapy for glioblastoma: current advances and future directions.
Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 174 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 3 syntheses or guidelines pooled it, 301 citations in OpenAlex.
- Impact of tumor treating fields on overall and progression-free survival in newly diagnosed glioblastoma: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.Frontiers in oncology · 2022Pooled it
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- Intratumoral therapeutic dust for chemo-photodynamic combination treatment.Science advances · 2026Article
- Health-related quality of life and its determinants in patients with malignant brain tumors: a prospective longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Optimization of electrode material and geometry to enhance TTFields-like anticancer effects in MCF-7 breast cancer cells.Scientific reports · 2026Article
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression.Signal transduction and targeted therapy · 2026Article
- Tumor treating fields combined with concurrent chemoradiotherapy for glioblastoma: A multi-institutional analysis.iScience · 2026Article
- Neuromodulation in Neuro-Oncology: A Scoping Review.Journal of personalized medicine · 2026Review
- Tumor Treating Fields and the Glioblastoma Microenvironment: Mechanistic Convergences with Radiotherapy.Cancers · 2026Review
- A sonoelectric artificial meningeal device for enhanced implantable electric field ablation of glioblastoma.Scientific reports · 2026Article
- Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study.Journal of neuro-oncology · 2026Article
- Virus-like particle vaccine targeting meningeal lymphatic vessels via intradural delivery activates anti-glioma immunity.Journal of neuro-oncology · 2026Article
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma.ChemMedChem · 2026Article
- RBM15B enhancing ITGA1 mRNA stability can accelerate glioblastoma tumorigenesis via the PI3K-Akt pathway.Discover oncology · 2026Article
- Silent forces, hidden currents: the influence of static magnetic field stimulation on tumor biophysics.npj biomedical innovations · 2026Review
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Increasing the measurable frequency range of magnetic field oscillations with off-resonance spin-lock preparation pulses.Magnetic resonance in medicine · 2026Article
114 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)-an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles-to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.